🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Europe stocks down as drugmakers slip; FTSE drops 0.63%

Published 03/22/2010, 05:10 AM
NDX
-
UK100
-
FCHI
-
DJI
-
DE40
-
STOXX50
-
SASY
-
Investing.com – European stock markets were down on Monday, as drugmakers slipped after the House of Representatives approved a far-reaching overhaul of the U.S. healthcare system.

During early European trade, France’s CAC 40 was down 0.62%; Germany's DAX slipped 0.48%; Britain's FTSE 100 was down 0.63%; and the EURO STOXX 50 shed 0.67%.

Pharmaceutical companies were among the worst performers, with Sanofi-Aventis dropping 1.38% and Roche shedding 0.8%, after House Democrats approved the health care reform, voting over Republican opposition to provide tens of millions of uninsured Americans with medical coverage.

Persisting concerns over Greece also hurt investor sentiment, as European leaders remained divided on whether their nations should provide the debt-laden country with financial aid.

The outlook for U.S. markets, meanwhile, was also dim: Dow Jones Industrial Average futures indicated a drop of 0.38%, S&P 500 Index futures pointed to a slide of 0.44% and Nasdaq 100 Index futures indicated a decline of 0.33%.

Later in the day, the European Central Bank president, Jean-Claude Trichet, was set to testify before the Economic and Monetary Affairs Committee of the European Parliament in Brussels.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.